Goodrich Consulting is a construction consultancy with over 30 years of project management and quantity surveying expertise. With a close-knit team of 26, the business’s unrivalled reputation has been built on the strength and competence of its long-standing partners and experienced technical staff. Employee health and wellness are at the core of its ethos, which has been a major contributor to the success of the company, and its impressive staff retention rates. In 2017, Leckie came to Goodrich as a Senior Project Manager, and over the last 5 years he has progressed to an Associate and become an integral part of the team at the Northampton office.
In 2022, Leckie was diagnosed with an inherited prion disease (GSS). His genetic mutation, E146G, has never been seen before and is being reported worldwide with a rarity value that cannot be measured in the recognised statistics for the disease. When the company heard the news of their valued colleague’s diagnosis it was a huge shock to them all, and Goodrich endeavoured to provide their support in whatever way they could to help Leckie and his family battle this terrible disease.
Working alongside John and the team at UCLH, Goodrich set up a JustGiving page and started spreading the word about Leckie’s condition across their social media platforms to help raise awareness of prion disease and The Cure CJD Campaign. It wasn’t long before the donations came pouring in, and the initial £10,000 target was hit and exceeded, so it was increased to £12,000. To continue their awareness campaign, and with Leckie being a keen walker, the company decided to organise a week of walking, where they were targeted to walk a minimum of 300 miles across a week in September, which would be the equivalent distance between their Northampton, Birmingham, Bristol, and Newquay offices. On the Friday, the team along with friends, family, colleagues, clients, consultants, and contractors collectively walked a 10-mile loop across the rolling Cotswold countryside followed by a well-earned lunch at a pub in Bourton-on-the-Water. It was a very memorable day for the company, and after walking an astonishing 757 miles in total over 5 days, they not only smashed their walking target, but their fundraising target too, as the JustGiving page hit over £23,000!
Even through these difficult times, Leckie is determined to remain positive and is thankful for the support network he has:
“Every day presents a new challenge be it mental, physical, or emotional and I feel privileged and truly humbled by the support from colleagues, clients, family, and friends. It gives me the motivation I need to keep a positive mental attitude given the very stark reality of this rare, critical, and untreatable illness.”
Goodrich’s Marketing Manager, Olivia Smith, has been at the forefront of the company’s fundraising efforts, working closely alongside Leckie and the team at The Cure CJD Campaign. She also challenged herself to run her first half marathon in September on behalf of the charity:
“It’s been incredibly heartwarming to see the amount of support that we have received for Leckie, his family, and the charity since the announcement of his diagnosis. Leckie’s unwavering courage, bravery and determination have been inspirational, and I feel privileged to be working with him and the team at The Cure CJD Campaign to raise awareness of prion disease, and the impact it has on the lives of those suffering and their loved ones. There may not be a cure yet, but I know that the team at Goodrich will continue fighting alongside Leckie so that together we can get closer to finding the answers.”
To help the charity raise its profile, Leckie decided to share his story and give a glimpse into the impact it has on the lives of those suffering, both physically and mentally. You can view this in the video below.
After the success of Leckie’s walk in September 2023, Goodrich has decided to make it an annual event to continue raising awareness and funds for this incredibly worthy cause. The money that they have raised to date will make a significant contribution towards the funds needed to support the vital research into new clinical trials.